In the spotlight for whom the bell tolls? A toll-like receptor 9 agonist’s journey from vaccine adjuvant to promising agent in anti–pd-1–resistant melanoma

Abstract

Developing effective therapies in anti–PD-1–resistant melanoma is a key unmet need. The combination of pembrolizumab with the intralesional TLR9 agonist vidutolimod showed promise in this patient population with correlative analysis suggesting that patients with a “cold” tumor immune microenvironment may be the best patients to study further.